The condition is caused by mutations in the TAFAZZIN gene, which is crucial for the proper metabolism of cardiolipin, a phospholipid that plays a vital role in mitochondrial function. Recent ...

The Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for elamipretide for the treatment of Barth syndrome, a rare genetic disorder.